ALEXION PHARMACEUTICALS INC's ticker is ALXN and the CUSIP is 015351109. A total of 565 filers reported holding ALEXION PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 1.22 and the average weighting 0.3%.
About ALEXION PHARMACEUTICALS INC
Alexion Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing and commercializing life-changing drugs for patients with rare and severe diseases. The company's mission is to transform the lives of patients with devastating and rare diseases by delivering innovative, life-changing therapies.
Alexion's flagship product is Soliris, a treatment for two rare and life-threatening blood disorders, paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris has been a game-changer for patients suffering from these diseases, providing them with a new lease on life.
In addition to Soliris, Alexion has a robust pipeline of products in development, including Ultomiris, a next-generation treatment for PNH and aHUS, and ALXN1840, a potential treatment for Wilson disease, a rare genetic disorder that causes copper to accumulate in the body.
Alexion's leadership team is comprised of experienced executives with a track record of success in the biopharmaceutical industry. Ludwig Hantson, the company's CEO, has a strong background in drug development and commercialization, having previously served as the CEO of Baxalta and as an executive at Novartis.
Overall, Alexion Pharmaceuticals Inc. is a company with a strong mission, a proven track record of success, and a promising pipeline of products in development. For investors looking to invest in a company that is making a real difference in the lives of patients with rare and severe diseases, Alexion Pharmaceuticals Inc. is definitely worth considering.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $1,117,000 | -47.7% | 11,474 | -40.1% | 0.15% | -16.6% |
| Q1 2018 | $2,134,000 | -27.5% | 19,150 | -8.8% | 0.18% | -37.5% |
| Q3 2017 | $2,945,000 | -10.9% | 20,995 | -22.7% | 0.28% | -6.7% |
| Q2 2017 | $3,304,000 | +184.1% | 27,154 | +185.8% | 0.30% | +111.3% |
| Q4 2016 | $1,163,000 | -79.4% | 9,500 | -79.4% | 0.14% | -77.0% |
| Q3 2016 | $5,656,000 | +409.5% | 46,154 | +385.5% | 0.62% | +341.4% |
| Q2 2016 | $1,110,000 | -77.0% | 9,507 | -72.6% | 0.14% | -78.9% |
| Q1 2016 | $4,831,000 | +375.5% | 34,700 | +492.0% | 0.66% | +66.6% |
| Q1 2015 | $1,016,000 | +138.5% | 5,861 | +154.3% | 0.40% | +123.6% |
| Q4 2014 | $426,000 | – | 2,305 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 364,274 | $56,914,000 | 16.62% |
| Sand Grove Capital Management LLP | 270,000 | $42,185,000 | 13.14% |
| Sarissa Capital Management LP | 797,740 | $124,638,000 | 12.72% |
| Prosight Management, LP | 175,738 | $27,457,000 | 12.69% |
| DSC Advisors, L.P. | 69,000 | $10,781,000 | 8.91% |
| Eversept Partners, LP | 376,200 | $58,777,488 | 6.90% |
| Camber Capital Management LP | 1,175,000 | $183,582,000 | 6.44% |
| Pentwater Capital Management LP | 2,961,000 | $462,627,000 | 5.59% |
| PFM Health Sciences, LP | 981,131 | $153,292,000 | 5.39% |
| WATER ISLAND CAPITAL LLC | 481,238 | $75,189,000 | 5.30% |